Cutaneous T-cell lymphoma (CTCL) is a relatively rare non-Hodgkin lymphoma (NHL).

NHL is divided into the more common B-cell lymphomas and the less frequent T-cell lymphomas. CTCL is a group of T-cell lymphomas that involve the skin, including mycosis fungoides, the most common type, as well as Sézary syndrome.

Patients with CTCL typically present with cutaneous patches, plaques or tumors. The type of skin lesions, extent of skin involvement, and the presence of extracutaneous disease are important prognostic factors.

Early-stage CTCL can typically be treated with topical therapies alone, such as retinoids and chlormethine gel. For progressive disease, therapeutic options include classical chemotherapy, extracorporeal photopheresis and systemic therapies such as mogamulizumab and brentuximab vedotin. There are exciting developments in both topical and systemic treatments for CTCL, with the aims to improve response rates, decrease progression and improve patients’ quality of life.

View Lymphoma Overview Page

Cutaneous T-Cell Lymphoma

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics.

The supporters have no influence over the production of the content.

Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a relatively rare non-Hodgkin lymphoma (NHL).

NHL is divided into the more common B-cell lymphomas and the less frequent T-cell lymphomas. CTCL is a group of T-cell lymphomas that involve the skin, including mycosis fungoides, the most common type, as well as Sézary syndrome.

Patients with CTCL typically present with cutaneous patches, plaques or tumors. The type of skin lesions, extent of skin involvement, and the presence of extracutaneous disease are important prognostic factors.

Early-stage CTCL can typically be treated with topical therapies alone, such as retinoids and chlormethine gel. For progressive disease, therapeutic options include classical chemotherapy, extracorporeal photopheresis and systemic therapies such as mogamulizumab and brentuximab vedotin. There are exciting developments in both topical and systemic treatments for CTCL, with the aims to improve response rates, decrease progression and improve patients’ quality of life.

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics.

The supporters have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter